Limits of observational data in determining outcomes from cancer therapy

Cancer

Volumn 112, Issue 11, 2008, Pages 2456-2466

  Giordano, Sharon H ^a   Kuo, Yong Fang ^b   Duan, Zhigang ^a   Hortobagyi, Gabriel N ^a   Freeman, Jean ^b   Goodwin, James S ^b  

^a UNIVERSITY OF TEXAS MD ANDERSON CANCER CENTER   (United States)

^b University of Texas Medical Branch School of Medicine   (United States)

Author keywords

Androgen deprivation; End Results; Epidemiology; Goserelin; Observational studies; Prostate cancer mortality; Selection bias; Surveillance

Indexed keywords

ANDROGEN; FLUOROURACIL; ANTIANDROGEN;

ADVANCED CANCER; AGED; ANDROGEN DEPRIVATION THERAPY; ARTICLE; CANCER ADJUVANT THERAPY; CANCER CENTER; CANCER CHEMOTHERAPY; CANCER EPIDEMIOLOGY; CANCER MORTALITY; CANCER RADIOTHERAPY; CANCER RESEARCH; CANCER RISK; CANCER THERAPY; COLON CANCER; COMORBIDITY; DATA BASE; DISEASE SEVERITY; HUMAN; LYMPH NODE METASTASIS; MAJOR CLINICAL STUDY; MALE; MORTALITY; OUTCOME ASSESSMENT; PATIENT SELECTION; PRIORITY JOURNAL; PROSTATE CANCER; TREATMENT OUTCOME; VALIDATION PROCESS; ADENOCARCINOMA; ADJUVANT CHEMOTHERAPY; CANCER REGISTRY; COLON TUMOR; LYMPH NODE; MIDDLE AGED; MULTIMODALITY CANCER THERAPY; NEOPLASM; PATHOLOGY; PROSTATE TUMOR; PROSTATECTOMY; SURVIVAL RATE;

ADENOCARCINOMA; AGED; AGED, 80 AND OVER; ANDROGEN ANTAGONISTS; CHEMOTHERAPY, ADJUVANT; COLONIC NEOPLASMS; COMBINED MODALITY THERAPY; HUMANS; LYMPH NODES; MALE; MIDDLE AGED; NEOPLASMS, HORMONE-DEPENDENT; PROSTATECTOMY; PROSTATIC NEOPLASMS; SEER PROGRAM; SURVIVAL RATE; TREATMENT OUTCOME;

EID: 47249165270     PISSN: 0008543X     EISSN: 10970142     Source Type: Journal    
DOI: 10.1002/cncr.23452     Document Type: Article

References (52)

1. Potosky AL, Riley GF, Lubitz JD, Mentnech RM, Kessler LG. Potential for cancer related health services research using a linked Medicare-tumor registry database. Med Care. 1993;31:732-748.
2. Du X, Freeman JL, Goodwin JS. The declining use of axillary dissection in patients with early stage breast cancer. Breast Cancer Res Treat. 1999;53:137-144.
3. Du X, Goodwin JS. Patterns of use of chemotherapy for breast cancer in older women: findings from Medicare claims data. J Clin Oncol. 2001;19:1455-1461.
4. Du X, Goodwin JS. Increase of chemotherapy use in older women with breast carcinoma from 1991 to 1996. Cancer. 2001;92:730-737.
5. Du XL, Osborne C, Goodwin JS. Population-based assessment of hospitalizations for toxicity from chemotherapy in older women with breast cancer. J Clin Oncol. 2002;20:4636-4642.
6. Patt DA, Goodwin JS, Kuo YF, et al. Cardiac morbidity of adjuvant radiotherapy for breast cancer [see comment]. J Clin Oncol. 2005;23:7475-7482.
7. Doyle JJ, Neugut AI, Jacobson JS, Grann VR, Hershman DL. Chemotherapy and cardiotoxicity in older breast cancer patients: a population-based study. J Clin Oncol. 2005;23:8597-8605.
8. Baxter NN, Tepper JE, Durham SB, Rothenberger DA, Virnig BA. Increased risk of rectal cancer after prostate radiation: a population-based study [see comment]. Gastroenterology. 2005;128:819-824.
9. Baxter NN, Habermann EB, Tepper JE, Durham SB, Virnig BA. Risk of pelvic fractures in older women following pelvic irradiation [see comment]. JAMA. 2005;294:2587-2593.
10. Shahinian VB, Kuo YF, Freeman JL, Goodwin JS. Risk of fracture after androgen deprivation for prostate cancer. N Engl J Med. 2005;352:154-164.
11. Schrag D, Rifas-Shiman S, Saltz L, Bach PB, Begg CB. Adjuvant chemotherapy use for Medicare beneficiaries with stage II colon cancer. J Clin Oncol. 2002;20:3999-4005.
12. Earle CC, Tsai JS, Gelber RD, Weinstein MC, Neumann PJ, Weeks JC. Effectiveness of chemotherapy for advanced lung cancer in the elderly: instrumental variable and propensity analysis. J Clin Oncol. 2001;19:1064-1070.
13. Sundararajan V, Mitra N, Jacobson JS, Grann VR, Heitjan DF, Neugut AI. Survival associated with 5-fluorouracil-based adjuvant chemotherapy among elderly patients with nodepositive colon cancer [summary for patients in Ann Intern Med. 2002;136:I19]. Ann Intern Med. 2002;136:349-357.
14. Neugut AI, Fleischauer AT, Sundararajan V, et al. Use of adjuvant chemotherapy and radiation therapy for rectal cancer among the elderly: a population-based study. J Clin Oncol. 2002;20:2643-2650.
15. Du XL, Jones DV, Zhang D. Effectiveness of adjuvant chemotherapy for node-positive operable breast cancer in older women. J Gerontol A Biol Sci Med Sci. 2005;60:1137-1144.
16. Hershman D, Fleischauer AT, Jacobson JS, Grann VR, Sundararajan V, Neugut AI. Patterns and outcomes of chemotherapy for elderly patients with stage II ovarian cancer: a population-based study. Gynecol Oncol. 2004;92:293-299.
17. Ramsey SD, Howlader N, Etzioni RD, Donato B. Chemotherapy use, outcomes, and costs for older persons with advanced nonsmall-cell lung cancer: evidence from Surveillance, Epidemiology and End Results-Medicare. J Clin Oncol. 2004;22:4971-4978.
18. Giordano SH, Duan Z, Kuo YF, Hortobagyi GN, Goodwin JS. Use and outcomes of adjuvant chemotherapy in older women with breast cancer [see comment]. J Clin Oncol. 2006;24:2750-2756.
19. Wong YN, Mitra N, Hudes G, et al. Survival associated with treatment vs observation of localized prostate cancer in elderly men. JAMA. 2006;296:2683-2693.
20. Grimes DA, Schulz KF. Bias and causal associations in observational research [see comment]. Lancet. 2002;359:248-252.
21. Wen SW, Hernandez R, Naylor CD. Pitfalls in nonrandomized outcomes studies. The case of incidental appendectomy with open cholecystectomy. JAMA. 1995;274:1687-1691.
22. Schrag D, Cramer LD, Bach PB, Begg CB. Age and adjuvant chemotherapy use after surgery for stage III colon cancer. J Natl Cancer Inst. 2001;93:850-857.
23. Sundararajan V, Hershman D, Grann VR, Jacobson JS, Neugut AI. Variations in the use of chemotherapy for elderly patients with advanced ovarian cancer: a population-based study. J Clin Oncol. 2002;20:173-178.
24. El-Serag HB, Siegel AB, Davila JA, et al. Treatment and outcomes of treating of hepatocellular carcinoma among Medicare recipients in the United States: a population-based study [see comment]. J Hepatology. 2006;44:158-166.
25. Iwashyna TJ, Lamont EB. Effectiveness of adjuvant fluorouracil in clinical practice: a population-based cohort study of elderly patients with stage III colon cancer [see comment]. J Clin Oncol. 2002;20:3992-3998.
26. Krzyzanowska MK, Weeks JC, Earle CC. Treatment of locally advanced pancreatic cancer in the real world: population-based practices and effectiveness. J Clin Oncol. 2003;21:3409-3414.
27. Urbach DR, Swanstrom LL, Hansen PD. The effect of laparoscopy on survival in pancreatic cancer. Arch Surg. 2002;137:191-199.
28. Charlson ME, Pompei P, Ales KL, MacKenzie CR. A new method of classifying prognostic comorbidity in longitudinal studies: development and validation. J Chronic Dis. 1987;40:373-383.
29. Romano PS, Roos LL, Jollis JG. Adapting a clinical comorbidity index for use with ICD-9-CM administrative data: differing perspectives. J Clin Epidemiol. 1993;46:1075-1079; discussion1081-1090.
30. Rubin DB, Thomas N. Matching using estimated propensity scores: relating theory to practice. Biometrics. 1996;52:249-264.
31. Rubin DB. Estimating causal effects from large data sets using propensity scores. Ann Intern Med. 1997;127(8 pt 2):757-763.
32. D'Agostino RB Jr. Propensity score methods for bias reduction in the comparison of a treatment to a nonrandomized control group. Stat Med. 1998;17:2265-2281.
33. Bolla M, Gonzalez D, Warde P, et al. Improved survival in patients with locally advanced prostate cancer treated with radiotherapy and goserelin [see comment]. N Engl J Med. 1997;337:295-300.
34. Pilepich MV, Caplan R, Byhardt RW, et al. Phase III trial of androgen suppression using goserelin in unfavorableprognosis carcinoma of the prostate treated with definitive radiotherapy: report of Radiation Therapy Oncology Group Protocol 85-31. J Clin Oncol. 1997;15:1013-1021.
35. Pilepich MV, Winter K, John MJ, et al. Phase III Radiation Therapy Oncology Group (RTOG) trial 86-10 of androgen deprivation adjuvant to definitive radiotherapy in locally advanced carcinoma of the prostate. Int J Radiat Oncol Biol Phys. 2001;50:1243-1252.
36. Mahoney FI, Barthel DW. Functional evaluation: the Barthel Index. Md State Med J. 1965;14:61-65.
37. Walter LC, Brand RJ, Counsell SR, et al. Development and validation of a prognostic index for 1-year mortality in older adults after hospitalization [see comment]. JAMA. 2001;285:2987-2994.
38. Karnofsky DA, Burchenal JH. The clinical evaluation of chemotherapeutic agents in cancer. In: Macleod CM, ed. Evaluation of Chemotherapeutic Agents. New York, NY: Columbia University Press; 1949:199-205.
39. Lee Y. The predictive value of self-assessed general, physical, and mental health on functional decline and mortality in older adults. J Epidemiol Commun Health. 2000;54:123-129.
40. Mossey JM, Shapiro E. Self-rated health: a predictor of mortality among the elderly. Am J Public Health. 1982;72:800-808.
41. Vuorisalmi M, Lintonen T, Jylha M. Global self-rated health data from a longitudinal study predicted mortality better than comparative self-rated health in old age. J Clin Epidemiol. 2005;58:680-687.
42. Benyamini Y, Blumstein T, Lusky A, Modan B. Gender differences in the self-rated health-mortality association: is it poor self-rated health that predicts mortality or excellent self-rated health that predicts survival? Gerontologist. 2003;43:396-405; discussion 372-375.
43. Fried LP, Kronmal RA, Newman AB, et al. Risk factors for 5-year mortality in older adults: the Cardiovascular Health Study [see comment]. JAMA. 1998;279:585-592.
44. Welch HG, Albertsen PC, Nease RF, Bubolz TA, Wasson JH. Estimating treatment benefits for the elderly: the effect of competing risks. Ann Intern Med. 1996;124:577-584.
45. Cochran WG. The effectiveness of adjustment by subclassification in removing bias in observational studies. Biometrics. 1968;24:295-313.
46. Austin PC, Mamdani MM, Stukel TA, Anderson GM, Tu JV. The use of the propensity score for estimating treatment effects: administrative versus clinical data. Stat Med. 2005;24:1563-1578.
47. Sturmer T, Schneeweiss S, Brookhart MA, Rothman KJ, Avorn J, Glynn RJ. Analytic strategies to adjust confounding using exposure propensity scores and disease risk scores: nonsteroidal anti-inflammatory drugs and short-term mortality in the elderly. Am J Epidemiol. 2005;161:891-898.
48. Reeves BC, van Binsbergen J, van Weel C. Systematic reviews incorporating evidence from nonrandomized study designs: reasons for caution when estimating health effects. Eur J Clin Nutr. 2005;59(suppl 1):S155-S161.
49. Brookhart MA, Schneeweiss S, Rothman KJ, Glynn RJ, Avorn J, Sturmer T. Variable selection for propensity score models. Am J Epidemiol. 2006;163:1149-1156.
50. Moertel CG, Fleming TR, Macdonald JS, et al. Levamisole and fluorouracil for adjuvant therapy of resected colon carcinoma [see comment]. N Engl J Med. 1990;322:352-358.
51. Concato J, Shah N, Horwitz RI. Randomized, controlled trials, observational studies, and the hierarchy of research designs [see comment]. N Engl J Med. 2000;342:1887-1892.
52. Benson K, Hartz AJ. A comparison of observational studies and randomized, controlled trials. N Engl J Med. 2000;342:1878-1886.